candesartan cilexetil
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Proteinuria
Conditions
Proteinuria
Trial Timeline
Apr 1, 2003 → Dec 1, 2006
NCT ID
NCT00242346About candesartan cilexetil
candesartan cilexetil is a phase 3 stage product being developed by AstraZeneca for Proteinuria. The current trial status is completed. This product is registered under clinical trial identifier NCT00242346. Target conditions include Proteinuria.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00690612 | Phase 3 | Completed |
| NCT00242346 | Phase 3 | Completed |
| NCT00252733 | Phase 3 | Completed |
Competing Products
6 competing products in Proteinuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zibotentan/Dapagliflozin + Dapagliflozin | AstraZeneca | Phase 2 | 52 |
| Zibotentan/Dapagliflozin + Dapagliflozin | AstraZeneca | Phase 3 | 77 |
| valsartan | Novartis | Approved | 85 |
| Belatacept | Bristol Myers Squibb | Phase 2 | 51 |
| Sparsentan | Travere Therapeutics | Approved | 80 |
| Losartan Potassium + Comparator: amlodipine besylate + Enalapril Maleate | Organon | Phase 3 | 72 |